MANNICH-TYPE N-ACYLATED b-AMINO ACID DERIVATIVES
1173
8.00–7.94 (m, 3H), 7.85–7.83 (d, J ¼ 8.4 Hz, 1H), 7.66–7.46 (m, 7H), 6.25–6.23
(d, 6 Hz, 1H), 3.76–3.73 (t, 2H), 3.66–3.60 (dd, J ¼ 8 and 17.6 Hz, 1H), 2.59–2.56
(t, 2H); 13C NMR (100 MHz, DMSO-d6): d 197.17, 168.10, 137.97, 137.95, 136.47,
133.42, 133.40, 133.32, 133.31, 133.30, 128.72, 128.68, 128.08, 128.05, 127.53,
126.36, 125.68, 123.19, 122.88, 45.09, 43.64, 40.94, 40.12, 39.92, 39.71; FT-IR
(KBr) c max 3283.21, 3062.41, 2969.84, 2904.27, 1683.55, 1649.80, 1596.77,
1551.45, 1447.31, 1359.57, 1272.79, 999.91, 801.27, 777.17, 755.95, 688.46 cmꢁ1
MS m=z 331.2 (M þ 1), 330.2 (Mþ), 229.1.
;
N-(1-(2-Bromophenyl)-3-oxo-3-phenylpropyl)-2-phenylacetamide (2i).
1H NMR, (400 MHz, DMSO-d6): d 8.64–8.62 (d, J ¼ 7.6 Hz, 1H), 8.00–7.97 (dd,
J ¼ 1.2 and 9.6 Hz, 2H), 7.67–7.62 (m, 1H), 7.59–7.50 (m, 3H), 7.44–7.36 (m, 1H),
7.35–7.32 (m, 1H), 7.28–7.18 (m, 6H), 5.66–5.63 (m, 1H), 3.54–3.51 (d, 10 Hz,
2H), 3.41 (s, 2H); 13C NMR (100 MHz, DMSO-d6): d 196.43, 169.29, 141.93,
136.32, 136.14, 133.34, 132.60, 128.89, 128.70, 128.08, 128.05, 127.84, 127.64,
126.25, 122.18, 48.80, 42.14, 40.10; FT-IR (KBr) c max 3297.68, 3061.44, 1680.66,
1655.59, 1547.59, 1447.31,1359.57, 1266.04, 1208.18, 1019.19, 752.10, 688.46 cmꢁ1
MS m=z 424.1 (M þ 2), 422.1 (Mþ), 229.1, 227.1.
;
N-(1-(2-Bromophenyl)-3-oxo-3-(4-acetoxyphenyl)propyl)benzamide (2j).
1H NMR, (400 MHz, DMSO-d6): d 8.89–8.87 (d, J ¼ 6.8 Hz, 1H), 8.08–8.06 (dd,
J ¼ 2 and 6.8 Hz, 2H), 7.83–7.81 (dd, J ¼ 1.2 and 8.4 Hz, 2H), 7.63–7.61 (dd,
J ¼ 1.2 and 8.0 Hz, 1H), 7.56–7.51 (m, 2H), 7.47–7.43 (dd, J ¼ 6.4 and 7.6 Hz, 2H),
7.39 (s, 1H), 7.29–7.27 (dd, J ¼ 2 and 6.8 Hz, 2H), 7.23–7.21 (dd, J ¼ 1.6 and
7.6 Hz, 1H), 5.88 (s, 1H), 3.81–3.74 (dd, J ¼ 10.4 and 17.6 Hz, 1H), 3.27–3.26 (d,
J ¼ 2.8 Hz, 1H), 2.29 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 196.04, 169.52,
166.46, 154.92, 143.05, 134.94, 134.67, 133.34, 131.99, 130.48, 129.57, 128.94,
128.69, 128.42, 128.00, 122.86, 122.80, 49.92, 43.74, 40.84, 40.63, 40.42, 40.21,
21.58; FT-IR (KBr) c max 3312.14, 1753.94, 1684.52, 1637.27, 1600.63, 1531.20,
1383.68, 1305.57, 1213.97, 1163.83, 1015.34, 991.23, 748.24, 696.17 cmꢁ1; MS m=z
466.1 (Mþ), 261.1, 227.1.
N-(1-(2-Bromophenyl)-3-oxo-3-phenylpropyl)benzamide (2k). 1H NMR,
(400 MHz, DMSO-d6): d 8.94–8.87 (m, 1H), 8.09–7.90 (m, 2H), 7.82–7.80 (m, 2H),
7.73–7.59 (m, 2H), 7.57–7.49 (m, 4H), 7.45–7.37 (m, 2H), 7.35–7.25 (m, 1H),
7.21–7.17 (m, 1H), 5.90–5.73 (m, 1H), 3.80–3.72 (dd, J ¼ 10.8 and 18.0 Hz, 1H),
3.26–3.25 (d, J ¼ 2.8 Hz, 1H); 13C NMR (100 MHz, DMSO-d6): d 197.08, 166.44,
143.09, 137.05, 134.94, 134.03, 133.34, 131.98, 129.57, 129.41, 128.94, 128.75, 128.
69, 128.44, 128.00, 122.80, 49.92, 43.78; FT-IR (KBr) c max 3327.57, 3055.66,
1686.44, 1634.38, 1578.45, 1529.27, 1354.75, 1230.36, 757.88, 693.28 cmꢁ1; MS m=
z 410.1 (Mþ), 409.1 (M-1), 229.1.
N-(1-(2-Chlorophenyl)-3-oxo-3-phenylpropyl)propionamide
(2o). 1H
NMR, (400 MHz, DMSO-d6): d 8.30–8.28 (d, J ¼ 7.6 Hz, 1H), 7.99–7.96 (dd,
J ¼ 0.8 and 8 Hz, 2H), 7.66–7.62 (m, 1H), 7.54–7.46 (m, 3H), 7.43–7.41 (dd,
J ¼ 1.6 and 8 Hz, 1H), 7.36–7.25 (m, 2H), 5.76 (s, 1H), 3.49–3.46 (d, J ¼ 9.6 Hz,
1H), 3.29–3.28 (d, J ¼ 4 Hz, 1H), 2.09–2.04 (dd, J ¼ 7.6 and 15.2 Hz, 2H),
0.96–0.92 (t, 3H); 13C NMR (100 MHz, DMSO-d6): d 196.59, 172.15, 140.58,
136.37, 133.30, 131.59, 129.31, 128.68, 128.49, 128.02, 127.58, 127.34, 46.16, 43.24,